PFO
PGNX

Pathstone Family Office’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Pathstone Family Office’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-504
Closed -$2K – 973
2019
Q1 		$2K Hold
504
– – ﹤0.01% 823
2018
Q4 		$2K Buy
+504
New +$2.57K ﹤0.01% 495

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Pathstone Family Office's PGNX Position: Q2 2019 in Review

Pathstone Family Office sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 504 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in PGNX in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

  • Pathstone Family Office reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 504 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $2K.
  • Pathstone Family Office first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 2 quarters.
  • Pathstone Family Office's Progenics Pharmaceuticals Inc position peaked at $2K in Q1 2019.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.